Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions.

[1]  L. Varticovski,et al.  Probing Fibroblast Growth Factor Dimerization and Role of Heparin-like Glycosaminoglycans in Modulating Dimerization and Signaling* , 2001, The Journal of Biological Chemistry.

[2]  Z. Shriver,et al.  Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor‐2 biological activity through different fibroblast growth factor receptors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  S. Shinjo,et al.  Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells. , 2001, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[4]  E. Antman.  The Search for Replacements for Unfractionated Heparin , 2001, Circulation.

[5]  T. Baglin,et al.  Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment , 2001, Journal of clinical pathology.

[6]  P. Kamp,et al.  Heparin cofactor II, antithrombin-beta and their complexes with thrombin in human tissues. , 2001, Thrombosis research.

[7]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[8]  J. Isner,et al.  Therapeutic angiogenesis for ischemic cardiovascular disease. , 2001, Journal of molecular and cellular cardiology.

[9]  R. Steinbrook,et al.  Health policy 2001--a new series. , 2001, The New England journal of medicine.

[10]  J. Turnbull,et al.  Heparan sulfate: decoding a dynamic multifunctional cell regulator. , 2001, Trends in cell biology.

[11]  Peter H. Seeberger,et al.  Automated Solid-Phase Synthesis of Oligosaccharides , 2001, Science.

[12]  R. Sasisekharan,et al.  Heparin and heparan sulfate: biosynthesis, structure and function. , 2000, Current opinion in chemical biology.

[13]  H. Kitagawa,et al.  Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. , 2000, Current opinion in structural biology.

[14]  M. Nugent.  Heparin sequencing brings structure to the function of complex oligosaccharides. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Biemann,et al.  Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  K. Biemann,et al.  Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Hansen,et al.  Physiological Function of Tissue Factor Pathway Inhibitor and Interaction with Heparins , 2000, Pathophysiology of Haemostasis and Thrombosis.

[18]  N. Perrimon,et al.  Specificities of heparan sulphate proteoglycans in developmental processes , 2000, Nature.

[19]  S. Tumova,et al.  Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. , 2000, The international journal of biochemistry & cell biology.

[20]  M. Nugent,et al.  Fibroblast growth factor-2. , 2000, The international journal of biochemistry & cell biology.

[21]  A. Friedl,et al.  Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Michael V. Doyle,et al.  Semirational design of a potent, artificial agonist of fibroblast growth factor receptors , 1999, Nature Biotechnology.

[23]  M. Salmivirta,et al.  Cell surface heparan sulfate proteoglycans and lipoprotein metabolism , 1999, Cellular and Molecular Life Sciences CMLS.

[24]  Z. Shriver,et al.  Sequencing complex polysaccharides. , 1999, Science.

[25]  N. Perrimon,et al.  Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. , 1999, Development.

[26]  J. Gallagher,et al.  Monomer Complexes of Basic Fibroblast Growth Factor and Heparan Sulfate Oligosaccharides Are the Minimal Functional Unit for Cell Activation* , 1999, The Journal of Biological Chemistry.

[27]  R. Linhardt,et al.  Heparinoids: structure, biological activities and therapeutic applications. , 1999, Planta medica.

[28]  J. Herbert,et al.  Synthesis of thrombin-inhibiting heparin mimetics without side effects , 1999, Nature.

[29]  E. Antman,et al.  Low-molecular-weight heparins: an intriguing new twist with profound implications. , 1998, Circulation.

[30]  U. Desai,et al.  Mechanism of Heparin Activation of Antithrombin , 1998, The Journal of Biological Chemistry.

[31]  J. Abrahams,et al.  The anticoagulant activation of antithrombin by heparin. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Weitz.  Low-molecular-weight heparins. , 1997, The New England journal of medicine.

[33]  J. J. Schwartz,et al.  Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? , 1997, The Journal of clinical investigation.

[34]  M. Salmivirta,et al.  Heparan sulfate : a piece of information , 2004 .

[35]  C L Cooney,et al.  Heparinase inhibits neovascularization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Gruber,et al.  A quest for the relief of atherosclerosis: potential role of intrapulmonary heparin--a hypothesis. , 1992, The Quarterly journal of medicine.

[37]  Z. Shriver,et al.  Direct isolation and sequencing of specific protein-binding glycosaminoglycans , 2001, Nature Medicine.

[38]  R. Rosenberg.  Redesigning heparin. , 2001, The New England journal of medicine.

[39]  D. Hoppensteadt,et al.  An update on heparins at the beginning of the new millennium. , 2000, Seminars in thrombosis and hemostasis.

[40]  G. Torri,et al.  Structural characterization of low molecular weight heparins. , 1999, Seminars in thrombosis and hemostasis.

[41]  J. Fareed,et al.  In vitro studies on the biochemistry and pharmacology of low molecular weight heparins. , 1999, Seminars in thrombosis and hemostasis.

[42]  G. Agnelli,et al.  Management of Oral Anticoagulant Therapy in Italy , 1999, Seminars in thrombosis and hemostasis.

[43]  J. Folkman,et al.  Control of angiogenesis by heparin and other sulfated polysaccharides. , 1992, Advances in experimental medicine and biology.